clinical trials for tirzepatide New Dual Incretin Agonist Type 2 Diabetes Semaglutide vs Tirzepatide results

Youll likely see the numbers on the scale drop more consistently and feel the benefits of your new habits

Global burden of type 2 diabetes in adolescents and young adults, 19902019: systematic analysis of the global burden of disease study 2019

Heres what we know about how Mounjaro works and what happens when people stop taking it

The following points detail the effectiveness of tirzepatide in clinical settings: Weight loss outcomes : Tirzepatide has shown to be superior to semaglutide, with patients losing an additional 12 pounds on average at the highest doses Clinical trials reveal that individuals without diabetes using tirzepatide experienced an average weight loss of 18%, with some losing as much as 21% of their body weight on a 15 mg weekly dose For people with diabetes, the average weight loss was around 12% when using tirzepatide A1C reduction and glucose control : In the SURPASS trials, tirzepatide demonstrated a more significant A1C reduction compared to semaglutide and placebo, with reductions of up to 2.1% from baseline levels The trials also noted substantial weight loss, with patients losing up to 12.9 kg (SURPASS-1) and 12.4 kg (SURPASS-2) Sustained efficacy : The SURMOUNT-4 study highlighted that adults using tirzepatide for weight management sustained an average weight loss of 26.0% over 88 weeks These findings underscore tirzepatides potential in providing a dual approach to treating type 2 diabetes and aiding in weight loss, attributed to its unique mechanism that targets both GLP-1 and GIP receptors

But the transition period can be confusing